Compare State Street SPDR Bloomberg High Yield Bond ETF (JNK) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR Bloomberg High Yield Bond ETF vs BIO-TECHNE Corp — how do they compare? State Street SPDR Bloomberg High Yield Bond ETF trades at $95.92, while BIO-TECHNE Corp trades at $71.58 (market cap $11.16B). The key difference: BIO-TECHNE Corp pays a 0.45% dividend while State Street SPDR Bloomberg High Yield Bond ETF pays none, and BIO-TECHNE Corp is trading nearer its 52-week high, State Street SPDR Bloomberg High Yield Bond ETF nearer its low. Which is the better fit depends on your goals.
| JNK | TECH | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $98.19 | $72.12 |
52-Week Low | $94.66 | $43.31 |
Market Cap | — | $11.16B |
Enterprise Value | — | $11.24B |
Dividend Yield | — | 0.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JNK trades at $95.95, down slightly by 0.03% with a bearish technical outlook from moving averages and oscillators. The ETF shows consistent dividend payments but lacks key financial ratio data for fundamental assessment. Recent news highlights bond market volatility and investor focus on high-yield opportunities amid Federal Reserve uncertainty.
The outlook remains cautious due to technical weakness and macroeconomic pressures from potential rate hikes. Risks include fee erosion over time and sensitivity to interest rate changes, while the current yield may appeal to income-focused investors in a volatile market environment.
Bio-Techne (TECH) trades at $71.64, down 0.67% today, near its 52-week high following Merck KGaA's $73 per share acquisition offer. The stock shows bullish technical signals with strong moving averages, though RSI indicates overbought conditions. Recent earnings have been mixed, with Q4 2025 beating expectations but Q1 2026 missing. The company maintains solid gross margins of 64.96% but faces declining net income margins, down to 6.01% in 2025 from 25.09% in 2023.
The outlook is heavily influenced by the pending acquisition, offering a clear exit near current levels. Risks include shareholder litigation over deal fairness and fundamental profitability pressures. With a high P/E of 103.03, the stock's upside appears capped without the deal, while the $73 bid provides a near-term floor. Investors should weigh acquisition completion probability against operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About State Street SPDR Bloomberg High Yield Bond ETF
JNK is a major ETF tracking the Bloomberg High Yield Very Liquid Index. It provides exposure to U.S. dollar-denominated junk bonds with above-average liquidity, featuring 2026 top holdings like EchoStar, Cloud Software Group, and Carnival Corp.
Read more on JNK →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
